Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock

Inclusion Criteria: * The patient or his/her representative was informed about the implementation of the study, its objectives, constraints and patient rights or emergency consent * The patient or his/her representative must haven given free and informed consent and signed the consent or emergency consent * The patient must be affiliated with or the recipient of a health insurance plan * Septic shock criteria: shock for which the suspected or proven starting point is an infection requiring vasopressors after adequate fluid resuscitation that started within the past 24 to 72 hours * Precharge independence criteria obtained: i.e. pulsed pressure variation \<13% or variation in ejection volume \<10% or variation in the cardiac index after passive lift leg \<10% or central venous pressure between 8 and 12 mmHg. * Antibiotic treatment in progress * Prescription ongoing vasopressor for 24 to 72 hours. * Sinus rhythm * Heart rate \> 100 beats per minute * Cardiac Index measured by thermodilution greater than 4.0 l / min / m\^2 * Central venous oxygen saturation \> 80% without positive inotropics such as dobutamine or isoproterenol (continuously taken or measured via central venous line in superior vena cava territory) on two successive samples in 12 hours * Monitoring of stroke volume (invasive, semi-invasive or ultrasound) Exclusion Criteria: * The patient is participating in another study * The patient has participated in another study in the last 3 months * The patient is in an exclusion period determined by a previous study * The patient is under any kind of guardianship * The patient is under judicial protection * The patient or his/her representative refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * The patient has a contraindication for a treatment used in this study * Cardiac index \< 4.0 l / min / m\^2 * Need to introduce a positive inotropic agent (as determined by the physician in charge of the patient) * Contraindications to the use of esmolol: Severe sinus bradycardia (less than 50 beats per minute); Sinus pathologies, severe disorders of atrioventricular conduction (without pacemaker), atrioventricular blocks of second and third degree; Cardiogenic shock; Severe hypotension; Decompensated heart failure; Untreated pheochromocytoma; Pulmonary hypertension; Acute asthma attack; chronic obstructive pulmonary disease; peripheral arterial disease; Metabolic acidosis; Known hypersensitivity to esmolol. * Patient with kidney failure (RIFLE Stage L) * Chronic treatment with beta blocker * Patient with ultrasound assessment of left ventricular ejection fraction \< 40%